Regeneron Pharmaceuticals Inc (REGN) Stake Raised by Millennium Management LLC
Millennium Management LLC grew its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 136.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 478,244 shares of the biopharmaceutical company’s stock after buying an additional 276,154 shares during the period. Millennium Management LLC’s holdings in Regeneron Pharmaceuticals were worth $179,801,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Harding Loevner LP raised its holdings in shares of Regeneron Pharmaceuticals by 589.2% during the third quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock valued at $286,619,000 after buying an additional 3,131,966 shares during the last quarter. Polen Capital Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 1.2% during the fourth quarter. Polen Capital Management LLC now owns 1,389,545 shares of the biopharmaceutical company’s stock valued at $522,413,000 after buying an additional 15,931 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 3.6% during the fourth quarter. Geode Capital Management LLC now owns 880,481 shares of the biopharmaceutical company’s stock valued at $330,385,000 after buying an additional 30,581 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 4.5% during the fourth quarter. Franklin Resources Inc. now owns 819,796 shares of the biopharmaceutical company’s stock valued at $308,212,000 after buying an additional 35,123 shares during the last quarter. Finally, Clearbridge Investments LLC raised its holdings in Regeneron Pharmaceuticals by 6.2% during the fourth quarter. Clearbridge Investments LLC now owns 806,762 shares of the biopharmaceutical company’s stock worth $303,310,000 after purchasing an additional 47,010 shares in the last quarter. 66.40% of the stock is currently owned by institutional investors.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $325.60, for a total transaction of $325,600.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 10.80% of the company’s stock.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share for the quarter, topping the consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same period in the previous year, the company posted $3.04 EPS. The company’s quarterly revenue was up 28.9% compared to the same quarter last year. equities research analysts forecast that Regeneron Pharmaceuticals Inc will post 19.2 EPS for the current fiscal year.
REGN has been the topic of several recent analyst reports. Canaccord Genuity reissued a “buy” rating and set a $522.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, February 7th. JPMorgan Chase & Co. boosted their target price on Regeneron Pharmaceuticals from $455.00 to $457.00 and gave the stock a “neutral” rating in a report on Wednesday, January 24th. Zacks Investment Research cut Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, February 5th. Evercore ISI dropped their target price on Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating on the stock in a report on Thursday, November 16th. Finally, Guggenheim set a $530.00 target price on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, February 9th. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $449.49.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.